ACCESS Newswire

Northway Biotech

Share
tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat

KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
tiakis Biotech AG and Northway Biotech collaboration
tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat

"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.

The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.

Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."

André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."

By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.

About Tiprelestat

tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.

About tiakis Biotech AG

tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).

About Northway Biotech

Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.

Contact Information

Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com

SOURCE: Northway Biotech

To view this piece of content from stats.newswire.com, please give your consent at the top of this page.

View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Latest GA Autonomous Jet Demo Features Live Air-to-Air Engagement Capability17.7.2025 18:10:00 CEST | Press release

Autonomous Tasking With TacACE and Optix.C2 Showcase Maturity and Operational Readiness SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 17, 2025 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and General Atomics Integrated Intelligence, Inc. (GA-Intelligence) successfully completed a groundbreaking demonstration on July 8, integrating technologies across multiple affiliates to showcase long-range kill chain effects, including an autonomous air-to-air engagement. The flight integrated local and global sensor fusion to deliver real-time situational awareness and autonomous tasking to an airborne MQ-20 Avenger® through the Tactical Autonomy Core Ecosystem (TacACE) to close the kill chain and showcase the system's maturity and operational readiness for the warfighter. The event featured the integration of a Collaborative Combat Aircraft (CCA), a fully compliant government-owned autonomy implementation, and beyond-line-of-sight (BLOS) Command and Control (C2). The MQ-20 unmanned jet,

Belgian Aircrew Completes MQ-9B Training17.7.2025 18:05:00 CEST | Press release

GA-ASI's MQ-9B SkyGuardian® Training Was Conducted at Multiple Sites, Including Flight Test & Training Center and Desert Horizon SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 17, 2025 / The first Belgian aircrew has completed training to operate the world's leading remotely piloted aircraft (RPA): the MQ-9B SkyGuardian®. General Atomics Aeronautical Systems, Inc. (GA-ASI), designer and developer of the MQ-9B, provided the extensive aircrew training that culminated at GA-ASI's Desert Horizon test facility in El Mirage, California, following stops in Belgium and GA-ASI's Flight Test & Training Center in North Dakota. "Providing all-encompassing training for the aircrews of our customers goes hand in hand with delivering the world's most capable RPA," said GA-ASI President David R. Alexander. "Completing this training ensures that Belgium is ready and able to operate their MQ-9Bs and maximize the benefits that come from long-range, high-endurance RPA." The scope of the training is focuse

A New Transatlantic Partnership for European CCA17.7.2025 18:00:00 CEST | Press release

General Atomics announces plans for rapid international uncrewed fighter development FAIRFORD, UK / ACCESS Newswire / July 17, 2025 / General Atomics is taking a bold step toward rapidly delivering a European Collaborative Combat Aircraft (CCA) - based on a mature U.S. platform, assembled in Europe, with European mission systems - by aligning its independent U.S. and German aerospace affiliates under a teamed operation.YFQ-42A The new aircraft is derived from the U.S. Air Force's YFQ-42A prototype, currently in ground testing and scheduled for first flight later this summer, designed and built by General Atomics Aeronautical Systems, Inc. (GA-ASI) in San Diego, Calif. European mission system customization and manufacturing in Europe will be supported by General Atomics' German aerospace affiliate, General Atomics Aerotec Systems GmbH (GA-ATS), headquartered in Oberpfaffenhofen, near Munich. Leveraging the prior investments of these established aerospace companies on both sides of the A

The Digital Banker17.7.2025 15:30:00 CEST | Press release

In this July 2025 article for the Fast Company Executive Board, Avtar Sehmbi of the Forbes Technology Council explains why Chief Technology Officers (CTOs) are increasingly positioned to lead the future of banking. LONDON, GB / ACCESS Newswire / July 17, 2025 / Artificial intelligence (AI) and other emerging technologies are reshaping banking by automating tasks, enhancing data analysis, and enabling personalized services. These tools improve risk management, streamline operations, and boost profitability. Institutions like JPMorgan Chase and Bank of America are already leveraging AI for fraud detection, customer service, and advanced analytics. Meanwhile, AI-powered hedge funds and neobanks use technology to deliver tailored experiences and outperform their peers.Avtar Sehmbi The Digital Banker Fast Company Avtar Sehmbi the Digital banker This shift isn't theoretical; it's already well underway. Digital systems are fully embedded into the everyday operations of financial institutions,

Global Sports Brand U.S. Polo Assn. Launches First Retail Store in Berlin, Germany16.7.2025 16:37:00 CEST | Press release

Brand Targets Aggressive Retail, Wholesale and Ecommerce Expansion WEST PALM BEACH, FL AND BERLIN, GERMANY / ACCESS Newswire / July 16, 2025 / U.S. Polo Assn., the official brand of the United States Polo Association (USPA), is proud to announce its first retail store in Germany alongside its brand partners Incom S.p.a. and Modevertrieb Sarnacchiaro GmbH (MVS). The location of the first U.S. Polo Assn. store in the heart of Berlin is at the premier Alexa Mall at Alexanderplatz and marks the beginning of a strategic retail rollout across the country, which solidifies the multi-billion-dollar brand's global presence in Germany. The new Berlin store is offering a curated selection of men's, women's, undergarments, and beachwear collections - a perfect mix of sports heritage and contemporary spirit.U.S. Polo Assn. Executives J. Michael Prince, Antonio Sarnacchiaro, and Lorenzo Nencini with U.S. Polo Assn. Models U.S. Polo Assn. is a symbol of style that blends sports inspiration and authen

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye